These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31332395)

  • 1. Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis.
    García-Deltoro M
    AIDS Rev; 2019; 21(2):55-64. PubMed ID: 31332395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.
    Boyd MA; Boffito M; Castagna A; Estrada V
    HIV Med; 2019 Mar; 20 Suppl 1():3-11. PubMed ID: 30724450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to start antiretroviral therapy?
    Wilkin TJ; Gulick RM
    Clin Infect Dis; 2008 Dec; 47(12):1580-6. PubMed ID: 18990069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?
    Rodger AJ; Sabin CA
    Curr Opin HIV AIDS; 2016 Sep; 11(5):487-491. PubMed ID: 27465878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update and review of antiretroviral therapy.
    Piacenti FJ
    Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dean Street clinics-battling London's MSM HIV epidemic.
    Kirby T; Thornber-Dunwell M
    Lancet HIV; 2018 May; 5(5):e210. PubMed ID: 29739698
    [No Abstract]   [Full Text] [Related]  

  • 12. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission.
    Kato M; Granich R; Bui DD; Tran HV; Nadol P; Jacka D; Sabin K; Suthar AB; Mesquita F; Lo YR; Williams B
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e142-9. PubMed ID: 23714739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why Everyone (Almost) with HIV Needs to Be on Treatment: A Review of the Critical Data.
    Farel CE; Dennis AM
    Infect Dis Clin North Am; 2019 Sep; 33(3):663-679. PubMed ID: 31248703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
    Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
    HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
    Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
    J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing the benefits of antiretroviral therapy for key affected populations.
    Grubb IR; Beckham SW; Kazatchkine M; Thomas RM; Albers ER; Cabral M; Lange J; Vella S; Kurian M; Beyrer C;
    J Int AIDS Soc; 2014; 17(1):19320. PubMed ID: 25043380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.